Dr. Masri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 SW Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-7400Fax+1 503-494-4749
Education & Training
Cleveland Clinic FoundationResidency, Internal Medicine, 2012 - 2015
Jordan University of Science and Technology FOMClass of 2011
Certifications & Licensure
OR State Medical License 2019 - 2025
PA State Medical License 2015 - 2021
OH State Medical License 2012 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
Publications & Presentations
PubMed
- 443 citationsMavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialIacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P. Abraham, Ahmad Masri
Lancet. 2020-09-12 - 72 citationsUnveiling Outcomes in Coexisting Severe Aortic Stenosis and Transthyretin Cardiac AmyloidosisHannah Rosenblum, Ahmad Masri, David L. Narotsky, Jeff Goldsmith, Nadira Hamid
European Journal of Heart Failure. 2021-02-01 - 18 citationsTemporal and Global Trends of the Incidence of Sudden Cardiac Death in Hypertrophic Cardiomyopathy.Omar M Abdelfattah, Matthew Martinez, Ahmed Sayed, Mohamed ElRefaei, Abdelrahman I Abushouk
JACC. Clinical Electrophysiology. 2022-11-01
Lectures
- The Role of Vasculature in Valvular Heart Disease2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Pulmonary Hypertension In Aortic and Mitral Valve Disease: Pathophysiology and Outcomes2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
- Case Presentation2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Press Mentions
New SEQUOIA-HCM Analysis Sheds Further Light on Benefits of Aficamten in Patients with oHCMSeptember 30th, 2024- New Drug Makes Exercise, Everyday Tasks Easier for People with Common Heart ConditionMay 13th, 2024
- Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 CongressMay 16th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
